Eliem Therapeutics, led by ex-Alder/Juno CEO Bob Azelby, raises $80M to advance ETX-810 and ETX-155
Eliem Therapeutics, a Seattle biotech led by former Juno and Alder exec Bob Azelby, raised $80 million to advance two drug candidates—ETX-810 for chronic pain and ETX-155 for depressive disorders and seizures—while planning to expand staff from 18 to 26 and operating from Seattle and Cambridge.
No comments yet.